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Abstract 
Background: Acute myeloid leukemia (AML) is clinically, cytogenetically, and molecularly 
heterogeneous. Advances in molecular research have greatly improved our understanding of the 
leukemogenesis in AML. Programmed cell death-4 (PDCD4) is a novel tumor suppressor that inhibits 
neoplastic transformation and tumor progression and invasion by suppressing activator protein (AP)-1 
activation and protein translation. In the present study, we examined the PDCD4 expression levels in 
de novo AML and investigated correlation between altered expression of PDCD4 with patients’ 
clinical characteristics.  
Methods: Peripheral blood samples were collected from 56 patients with AML at the time of 
diagnosis and also, 10 healthy individuals. Quantification of PDCD4 mRNA expression by Real Time 
Quantitative PCR was performed. Mann-Whitney U test was used to compare PDCD4 expression 
differences among healthy and AML samples. 
Findings: PDCD4 mRNA expression was significantly diminished in patients with AML at diagnosis 
in comparison to the PB as normal samples (P < 0.001). We observed a statistically lower expression 
in AML-M5 subtype in comparison to other AML subtypes (P = 0.028)  . We have not found any 
significant correlation between PDCD4 expression level and clinical parameters of patients. Also, no 
significant correlation between the expression levels of PDCD4 and complete remission after 
induction therapy was observed. 
Conclusion: Our results shown that, like many epithelial cancers, the down-regulation of PDCD4 
expression also occurs in AML. 
Keywords: Acute myeloid leukemia, Programmed cell death-4, Tumor suppressor gene 
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